Xeris Biopharma Holdings, Inc.

NASDAQ:XERS

Biotechnology

Healthcare
$16.99 +0.58%

+$0.04 today

Market cap
$3.10B
Beta
0.90
P/E (TTM)
98.7
EPS (TTM)
$0.07
52W Low $4.40High $10.08

Volume 2.76M

Average 1.66M

XERS Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Xeris Biopharma Holdings, Inc.NASDAQ: XERS

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue growth accelerates

Q1 FY2026 cost of revenue of $13.28M rose 52.2% year over year, ahead of the +37.0% change in trailing-twelve-month cost of revenue. Sequentially, it fell 30.4% from the prior quarter. Over 3 fiscal years it compounded at +33.1% a year.

Context

  • Cost of revenue amounted to 18.3% of revenue in FY2025, up 0.2 pp from a year earlier.
  • Cost of revenue increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +52.2% holds above the trailing-twelve-month pace of +37.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$13.28M-30.4% QoQ
Last fiscal yearDec 2025
$53.41M+45.0% YoY
LTMMar 2026
$57.97M+37.0% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+52.2%——
1 year+45.0%——
3-year CAGR+33.1%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
53.41M USD
Year-over-year change
+45.0%
4-year CAGR
+41.5%

Cost of Revenue vs competitors

How XERS compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +37.0% is the 2nd highest of 6, against a peer median of +24.0%.
  • Cost of revenue amounts to 18.4% of revenue for XERS, versus a peer median of 9.4%.
XERS Competitors
Cost of Revenue for XERS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ASNDAscendis Pharma A/SLTM Sep 2026€113.42M EUR+32.9%+104.1%9.4%
MNKDMannKind CorporationLTM Mar 2026$86.73M USD+14.8%+2.1%24.0%
XERSXeris Biopharma Holdings, Inc.LTM Mar 2026$57.97M USD+37.0%+33.1%18.4%
ETONEton Pharmaceuticals, Inc.LTM Mar 2026$39.32M USD+96.0%+75.1%45.2%
CORTCorcept Therapeutics IncorporatedLTM Jun 2026$14.09M USD+20.8%+34.1%1.7%
SEPNSepterna, Inc.LTM Sep 2026$421K USD——0.4%
GHRSGH Research PLCLTM Mar 2026$268K USD———
MBXMBX Biosciences, Inc. Common StockLTM Sep 2026$124K USD+24.0%——
SPRBSpruce Biosciences, Inc.LTM Mar 2026$0 USD———
Peer median (excluding XERS) —+24.0%+54.6%9.4%

Competitors are the stored peer set for XERS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue49.59M110.25M163.91M203.07M291.85M
Cost of Revenue13.32M22.63M28.65M36.83M53.41M
Gross Profit36.27M87.61M135.27M166.24M238.43M
Gross Margin73.1%79.5%82.5%81.9%81.7%
Research & Development25.16M20.97M22.34M25.56M31.17M
Selling, General & Admin125.72M137.75M146.1M163.48M182.37M
Operating Expenses151.43M169.55M179.28M199.88M213.54M
Depreciation & Amortization1.88M12.67M13.16M12.63M12.16M
EBITDA(113.67M)(69.31M)(23.74M)(13.99M)12.71M
EBITDA Margin-229.2%-62.9%-14.5%-6.9%4.4%
Operating Income(115.16M)(81.94M)(44.01M)(33.65M)24.9M
Operating Margin-232.2%-74.3%-26.8%-16.6%8.5%
Interest Income313K2.58M4.75M5.32M4.74M
Interest Expense7.18M14.1M26.61M33.18M29.08M
Other Income / Expenses(7.57M)(14.14M)(19.49M)(23.46M)(24.34M)
Income Before Tax(122.73M)(96.08M)(63.5M)(57.1M)554K
Pre-Tax Margin-247.5%-87.2%-38.7%-28.1%0.2%
Income Tax Expense0(1.42M)(1.25M)(2.27M)0
Net Income(122.73M)(94.66M)(62.26M)(54.84M)554K
Net Margin-247.5%-85.9%-38.0%-27.0%0.2%
EPS (Basic)(1.55)(0.70)(0.45)(0.37)0.00
EPS (Diluted)(1.55)(0.70)(0.45)(0.37)0.00
Weighted Avg Shares79.03M135.63M137.67M146.77M160.43M
Weighted Avg Shares (Diluted)79.03M135.63M137.67M146.77M172.74M

Xeris Biopharma Holdings, Inc.

NASDAQ:XERS

Intrinsic Alpha fair value

Locked

Current Price

$16.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.